×
GeneDx Holdings Net Cash Flow 2020-2025 | WGS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
GeneDx Holdings net cash flow from 2020 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
View More
GeneDx Holdings Net Cash Flow 2020-2025 | WGS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
GeneDx Holdings net cash flow from 2020 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company Name
Market
Cap
Danaher (DHR)
$133.5B
Elevance Health (ELV)
$96.1B
CVS Health (CVS)
$84.8B
Cencora (COR)
$55.6B
DiDi Global (DIDIY)
$20.3B
Natera (NTRA)
$20B
BioMerieux (BMXMF)
$15.6B
Solventum (SOLV)
$11.5B
ICON (ICLR)
$11.3B
EUROFINS SCIENT (ERFSF)
$11.1B
Revvity (RVTY)
$11B
CochLear (CHEOY)
$10.9B
Avantor (AVTR)
$10.3B
Doximity (DOCS)
$9.9B
Viatris (VTRS)
$9B
Medpace Holdings (MEDP)
$9B
Sonic Healthcare (SKHHY)
$7.7B
HealthEquity (HQY)
$7.3B
Charles River Laboratories (CRL)
$5.2B
Amplifon S.p.A (AMFPF)
$4.3B
Bausch + Lomb (BLCO)
$4.3B
Alignment Healthcare (ALHC)
$3.5B
Sotera Health (SHC)
$3B
BrightSpring Health Services (BTSG)
$2.9B
Organon (OGN)
$2.9B
Surgery Partners (SGRY)
$2.7B
Concentras Parent (CON)
$2.6B
Progyny (PGNY)
$1.8B
Ardent Health Partners (ARDT)
$1.8B
Premier (PINC)
$1.8B